News Hub | News Direct

News Release

Nevis Brands CEO reveals success story and future growth plans

Nevis Brands

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to provide an update on the company's operations, which they say is very different from most listed cannabis companies. Nevis Brands is a provider of cannabis brands in the United States and offers expansion opportunities worldwide. The company currently supplies products in Washington, Oregon, California, Ohio, Arizona, and Colorado through partnerships and licensees. The company has announced they have been approved for listing on the Canadian Securities Exchange under the ticker “NEVI.” Kueber explained one of their flagship products is Major, which has established itself as one of the best-selling cannabis beverages globally. Major was launched in March 2019 by the creators of Happy Apple, quickly gaining recognition as the top-selling THC beverage in Washington State. What sets Major apart is its utilization of SōRSE, a proprietary water-soluble emulsion technology. This technology enhances the consumption experience of cannabis, making it easier, safer, and more enjoyable. With an average onset time of 8-15 minutes, consumers no longer have to wait for a significant cannabis experience. Nevis Brands continues to innovate in the cannabis industry, offering high-quality products and leveraging cutting-edge technology to provide consumers with exceptional cannabis experiences. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

July 13, 2023 03:46 PM Eastern Daylight Time

Video

NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst

NanoViricides

Proactive research analyst John Savin speaks to Thomas Warner after releasing a new report on NanoViricides Inc (NYSE-A:NNVC), a development-stage company that is creating special-purpose nanomaterials for antiviral therapy. Savin gives an overview of what the company does, as well as its current operations and its financial situation. He highlights that NanoViricides is currently undertaking its first ever clinical trial, of an edible treatment for Covid-19 in India. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

July 13, 2023 08:31 AM Eastern Daylight Time

Video

Symbiome Partners with THG Ingenuity to Scale E-Commerce Offerings

Symbiome

Symbiome, a leading microbiome-nourishing skincare company, has announced a partnership with THG Ingenuity – an end-to-end direct-to-consumer (DTC) partner of choice for brands looking to connect with consumers through a multichannel commerce approach. The collaboration will focus on leveraging THG’s extensive reach to expand Symbiome’s offering globally. “Right now, nearly all our customers are in America. THG’s global footprint, and end-to-end platform, will allow us to seamlessly fulfill into Europe, the Middle East, and throughout the South-East Asian region,” said Adam Klausner, Symbiome’s Chief Operating Officer. According to Lane Barrocas, THG’s Vice President of eCommerce for North America, THG is experiencing a significant uptick of interest by consumers shopping for science-based skincare, particularly in the microbiome vertical. “Our partnership with Symbiome will allow them to quickly, efficiently and profitably grow and scale their DTC business, while helping to build brand awareness and creating a halo-effect, as they expand into other points of distribution within the market.” About Symbiome Symbiome is a San Francisco-based microbiome biotechnology company focusing on health and wellness. They are the developers of the Symbiome ® brand of BioIntact ® fermented skincare products that nourish and protect the skin and its microbiome, restoring what our skin has lost in the modern world. Symbiome has sponsored three international academic research expeditions deep into the Amazon rainforest, defining an evolutionary reference for the microbiome and transforming our understanding of the healthy human microbiome. Symbiome scientists have translated this groundbreaking research into a line of unique, proprietary skincare products formulated with naturally fermented, Amazonian botanicals. The brand's skincare lineup includes ten clean, organic, sustainable, and traceable products — each with less than eight ingredients. Learn more about Symbiome, and follow Symbiome on Instagram, LinkedIn and Facebook. About THG Ingenuity THG Ingenuity is a unified commerce platform with full stack technology, digital and operations omnichannel capabilities, parented by THG Holdings plc, a vertically integrated, digital-first consumer brands group, retailing its own brands plus third-party brands, via its e-commerce technology, infrastructure, and brand-building expertise. Contact Details BPCM Ali Taekman ali@bpcm.com Company Website https://www.symbiome.com

July 12, 2023 09:30 AM Eastern Daylight Time

Image

Revenue Increased 72% In Q1 2023 For Premier Packaging Corporation, A DSS, Inc. (NYSE: DSS) Wholly Owned Subsidiary

DSS, Inc.

By David Willey, Benzinga DSS, Inc. (NYSE American: DSS), a multinational company operating through strategic acquisitions and business development, released its financial results for the first quarter of 2023. The company, which operates nine business divisions and 40 subsidiaries, reported a significant reduction in operating losses and continued operations optimization. The quarter’s biggest news, however, came from DSS’s most established business segment– product packaging. The company’s Premier Packaging unit saw a 72% revenue increase compared to the same period in 2022. The increase was likely largely a result of the company’s capital investment in state-of-the-art equipment and facilities which expanded capacity and enhanced operational efficiency. With these revenue results, DSS looks to be positioning itself and its wholly-owned subsidiary, Premier Packaging Corporation, in a sector with growth potential. The global packaging and protective packaging market was worth $1 trillion in 2021 and is predicted to reach $1.5 trillion by 2031, growing at a compound annual growth rate (CAGR) of 4.3% during the forecast period. Other companies in the printing and distribution sector include Shapeway Holdings Inc. (NYSE: SHPW) and Ennis Inc. (NYSE: EBF). Significantly for Premier Packaging is the packaging industry’s migration from plastics to fiber packaging, which is 100% of Premier’s product mix. The company seems to be benefiting from huge market demand for highly decorative and branded secondary packaging– a key strength in Premier’s business plan. The company reports that its top-tier solutions provide a comprehensive packaging service, and its scalable model means it can fulfill any size order from any size company. Read more about DSS’s Premier Packaging solution here. Zacks SCR Analyst Predicts DSS Stock Price Has Potential To Increase By A Triple-Digit Percentage In its Q1 financial report, DSS also announced that operational loss decreased by 24% for Q1 of 2023 vs. Q1 of 2022. Total costs and expenses had also been reduced by 16% year-over-year (YoY), and net cash increased by investment activity by 115% YoY. Following the Q1 financial statement, a report was issued by Zacks Small Cap Research (SCR), a division of Zacks Investment Research. Zacks estimates that DSS’s stock price has the potential to increase from its present value of $0.37 (as of 7/7/23) to $1.50. Zacks SCR credits DSS’s growth into a multi-industry company with its strong record of opportune acquisitions. In its research report, the analyst also highlighted the strong revenue performance of Premier Packaging Corporation, as well as an upcoming biopharma spin-off which should raise $30 to $50 million through its initial public offering (IPO). DSS is preparing for the spin-off of biopharma Impact BioMedical, where a successful spin-off could result in growth for the company as a whole. DSS’s goals for 2023 involve doubling down on its positive results from the Q1 report. The company is maintaining a key strategic focus on ramping up revenue and customer diversification in the Premier Packaging division. Subsequent to the 1Q report, DSS has also announced the spinoff of its Impact BioMedical subsidiary to DSS shareholders, highlighting DSS’s innovative business plan of periodically distributing stock dividends to its shareholders. Jason Grady, COO of DSS, said, “We continue to execute our business plan of incubating promising businesses to build shareholder value, either through the distribution of a stock dividend in a spinoff or adding a separately traded equity to our balance sheet.” DSS, Inc. appears to have the potential to reward investors with improving fundamentals at the current low market valuation and the beginning of a stock dividend plan as subsidiaries are prepared for eventual spinoff to DSS shareholders. Learn more about what DSS, Inc. is doing to support and spin off businesses. DSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. These companies offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers, but also create sustainable value and opportunity for transformation. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice Contact Details Rick Lutz- TraDigital IR rick@tradigitalir.com Company Website https://www.dssworld.com/

July 12, 2023 09:00 AM Eastern Daylight Time

Cellular Goods provides update on King Tide Carbon integration

Cellular Goods PLC

Cellular Goods PLC (LSE:CBX) chairman and interim CEO Darcy Taylor speaks to Thomas Warner from Proactive about how the acquisition of biosynthetic algae & seaweed carbon sequestration as-a-service company King Tide Carbon (KTC) has been proceeding since it completed back in May. Taylor says that the acquisition of King Tide Carbon has allowed Cellular Goods to expand its vision of sustainability and capitalise on the increasing demand for carbon removal solutions driven by the Paris Climate Agreement. He goes on to emphasise the importance of bio-synthetics as an emerging technology for carbon removal and highlighted the expertise of the King Tide team in accelerating the company's direction. With the acquisition, Cellular Goods aims to be at the forefront of scalable and high-quality carbon removal solutions, contributing to the fight against climate change while delivering value to shareholders. He also addresses how long he is likely to stay in the interim CEO role, saying that his main priority is to deliver growth and development for the business and that he "remains committed for the next twelve months and beyond." He also commits to providing more frequent updates to shareholders. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 12, 2023 06:16 AM Eastern Daylight Time

Video

Mechelle Evans Announces GlowByMe, Her New Skincare Company

Client Valley

Las Vegas, NV - Mechelle Evans, the founder of GLO by ME SKIN, is pleased to announce her new company dedicated to revolutionizing the skincare industry. With a focus on providing excellent services and education, Mechelle is transforming the way individuals care for their skin. Mechelle, an esteemed Aesthetician, believes that healthy and glowing skin is a birthright for everyone. Recognizing the skin as the body's largest organ, she emphasizes the importance of proper skincare. Through a comprehensive range of services, Mechelle helps her clients achieve their skin goals, whether it's combating acne, reducing wrinkles, or maintaining overall skin health. However, Mechelle's mission extends beyond offering services; she is dedicated to educating individuals about the significance of skincare. She emphasizes the harmful effects of UV rays and environmental pollutants on the skin, which can lead to premature aging and other skin conditions. By instilling the importance of regular facials, proper cleansing, and the use of high-quality products, Mechelle empowers her clients to protect and enhance their skin's health. Mechelle's journey into skincare began in the early 1990s when she worked as a television extra. Witnessing the damage caused by heavy makeup and sun exposure, she became determined to maintain her own skin's health. Her introduction to Dr. Obagi, a renowned skincare expert, solidified her belief in the transformative power of skincare, prompting her to further educate herself on the subject. Motivated by her passion for helping others achieve clear and healthy skin, Mechelle made the life-changing decision to become a full-time aesthetician. Despite leaving behind a six-figure salary, she was driven by a greater purpose. Mechelle aimed to make a lasting impact on people's lives and be remembered for making a real difference. As an advanced licensed professional specializing in melanated skin, Mechelle offers a wide range of services, personalized skincare recommendations, and advanced treatments like chemical peels, microneedling, and lasers. Her goal is to provide effective solutions tailored to diverse skin tones, challenging prevailing mindsets that discourage treatment for such skin types. Driven by her dedication to delivering results, Mechelle embarked on creating her own skincare line. Her flagship product, a 1% retinol, stands out for its ability to address multiple skin types and deliver exceptional results. Infused with powerful antioxidants, essential amino acids, minerals, and botanical moisturizers, this retinol promotes healthy cell regeneration and collagen production, resulting in reduced visible signs of aging, diminished pores, and blemishes. Through GLO by ME SKIN, Mechelle Evans is redefining skincare by combining the power of education, quality treatments, and effective products. With her advanced knowledge, personalized approach, and commitment to inclusivity, she has become a trusted advisor and advocate for skin health. In a world where healthy skin is highly valued, Mechelle's vision of empowering individuals to embrace their natural beauty and achieve a healthy complexion is becoming a reality. Her expertise, passion, and transformative results have earned her a reputation as a leading force in the skincare industry. As Mechelle continues to leave her mark on the field, her dedication and expertise are changing lives. Through GLO by ME SKIN, she is making a genuine difference, leaving a lasting legacy as someone who revolutionized skincare and helped individuals achieve radiant, healthy skin. About Mechelle Evans: Mechelle Evans is the founder of GLO by ME SKIN, a skincare brand dedicated to providing innovative and effective skincare solutions. With a passion for skincare and a commitment to education, Mechelle offers personalized services and products to help individuals achieve healthy and radiant skin. Her expertise and transformative results have earned her recognition as a trusted advisor in the skincare industry. Contact Details GLO by ME SKIN Crissy Henry office@9figuremedia.com Company Website http://www.globyme.com/

July 11, 2023 05:24 PM Eastern Daylight Time

Image

Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?

NanoViricides, Inc.

By David Willey, Benzinga Read the latest report on NanoViricides here. NanoViricides (NYSE American: NNVC) has begun trials for its new drug candidate, NV-CoV-2 — an exciting development for the biotech company, as it starts its first human trials with drug sponsor Karveer Meditech Pvt. Ltd. India, the company’s licensee and co-developer in India. NanoViricides has been building out a novel nanomedicine platform for many years, and this platform now includes a pipeline of multiple preclinical antiviral drugs. The Company is developing antiviral medications that are built on the company’s patented nanoviricide technology. Nanomedicine has a lot of promise, but there are almost no nanomedicines available on the market to treat viral infections. Because of prior acquired expertise, NanoViricides’ first-in-class COVID drug, NV-CoV-2, took just about one year to complete IND-enabling studies, from the discovery stage in January 2020. As a small company with a novel mechanism implemented using out-of-the-box technologies, it took the Company much longer time to actually start clinical trials. Now that it has this regulatory experience, additional drug developments should not take such a long lag time. “We believe these clinical trials are an important milestone not only for NanoViricides and Karveer Meditech, India, but also for the advancement of treatments against all viral infections worldwide,” said Dr. Anil Diwan, President and Executive Chairman of NanoViricides. NanoViricides’ Treatment Of Coronaviruses The company’s first drug candidate is NV-CoV-2, a broad-spectrum, anti-coronavirus treatment. Other companies have developed treatments for COVID-19, These include Molnupiravir from Merck & Co. (NYSE: MRK), Paxlovid from Pfizer Inc. (NYSE: PFE) and Remdesivir from Gilead Sciences, Inc. (NASDAQ: GILD). However, there are limitations or drawbacks to each of these treatments. As a broad-spectrum anti-coronavirus drug, NV-CoV-2 has been shown to work against a variety of unrelated coronaviruses. This suggests that different strains or mutations are unlikely to escape the drug. Several common coronavirus strains include hCoV-229E, hCoV-OC43, hCoV-HKU1, and hCoV-NL63, which recur seasonally. Of these, NL63 and OC43 present with pneumonia similar to the delta COVID variant in susceptible patients, leading to fatalities at rates that are comparable to seasonal influenza. Now, SARS-CoV-2 with its variants is added to this list as a commonly occurring coronavirus. A Nanomedicine Platform For Other Viruses The trials for NV-CoV-2 are part of the company’s development of a novel platform technology employing nanoviricides. The NV-CoV-2 drug contains NV-387, a first-in-class chemical nanomedicine, and its unique mechanism of action (MoA) doesn’t rely on the patient’s immune system to destroy the virus. The Company says that NV-387 mimics an attachment receptor family to which over 90% of known viruses bind, and NanoViricides hopes that NV-387 will likely be a clinically effective drug against at least a few of these viruses. The Company has said that it has begun R&D work to expand the indications of NV-387 to other viruses. By bringing NV-CoV-2 to human trial, NanoViricides has demonstrated the platform’s capability to deliver a clinically relevant antiviral. After the Phase 1 studies are completed, the safety and tolerability data will be applicable to any other viruses that the Company targets using NV-CoV-2, assuming it can demonstrate pre-clinical success. Then NV-387 can directly enter Phase 2 as an antiviral against such additional viruses — which would likely mean significant cost and time savings for the additional indications, and substantial improvement in the return on investment (ROI) for the Company with commensurate benefits to the investors. The Company is not a “one-trick pony” either. It already has NV-HHV-1, a drug to treat shingles rashes, that has completed pre-clinical studies. The company believes its platform could provide treatments for a host of viruses, including other herpesviruses (cold sores, genital ulcers, and many other serious diseases), as well as influenza and HIV. This would position NanoViricides at the intersection of multiple growing treatment markets. The herpes treatment market was worth $1.5 billion in 2022 and is predicted to grow at a compound annual growth rate (CAGR) of 9.2% over the next seven years. The influenza market is expected to reach $1.2 billion by 2026, while the HIV market is predicted to reach $36 billion by 2027. For now, however, the company is keeping laser-focus on the development of NV-CoV-2 for treating COVID-19 and long COVID. Its current trial will test the drug’s safety and efficacy, and the data will be used to prepare for phase 2 trials. “NV-CoV-2 is aimed at satisfying the as-yet-unmet medical need of a highly effective broad-spectrum, anti-coronavirus drug that can be used for all patient populations,” said Diwan. “Moreover, it brings into the clinic a novel platform technology of attacking viruses to develop highly effective antiviral drugs.” Learn more about how NanoViricides is tackling different viruses by visiting its website. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

July 11, 2023 09:25 AM Eastern Daylight Time

Fawn River Cultivation Company and BioLumic Unleash a New Era of Cannabis Varieties in Michigan

BioLumic

Fawn River Cultivation Company and BioLumic announced today a new partnership to redefine cannabis cultivation in Michigan using BioLumic’s patented UV light technology, opening the door for new varieties to hit the consumer market by the end of 2023. “The BioLumic technology will enable the creation of varieties with unique wellness benefits and extraordinary experiences,” said John Babcock, CEO, Fawn River Cultivation Company. “Michigan consumers deserve more varieties with a greater value at every price point. In addition to curating best-in-class genetics to expand our product line, we look for innovative partners like BioLumic to help us meet the quickly changing market.” Now the nation’s second-largest cannabis market, the state of Michigan has positioned itself as a national leader in the cannabis industry. Fawn River services approximately 100 provisioning centers in the Michigan cannabis market with two retail locations in the Great Lake State. Through this partnership, Fawn River will deploy BioLumic’s propagation-stage light recipes to regulate cannabinoids and terpenes profiles to develop a wider and more compelling range of consumer products and consumer wellness benefits. “Fawn River is a vertically-integrated cannabis company with a state-of-the-art cultivation facility, experienced team and a true understanding of what the Michigan cannabis consumer values in its varieties,” said Steve Sibulkin, CEO, BioLumic. “This partnership has the potential to redefine cannabis market dynamics in Michigan by ushering in a new era of products and product development.” Built on two decades of plant science, BioLumic’s UV Light Signal Recipe™ platform is based on the established science of photomorphogenesis – the ability to regulate the genetic expression of plants with light. It combines plant genetic insights, wide-ranging plant response data and a software and hardware platform that can deploy trillions of short-duration ‘light recipes.’ BioLumic’s Light Recipes™ are a targeted, programmed sequence of light spectrum exposure which activate positive growth responses in seeds and young plants. “The proprietary nature of the BioLumic light treatment pairings ensures defensible gains in an industry marked by quick-changing demands,” said Babcock. “It also allows us to go beyond cultivating top strains alone to create ongoing advantages that not only sets Fawn River apart in the industry but continue to improve our offering to consumers at an unbelievable pace.” To learn more, visit biolumic.com or fawnrivercc.com. About BioLumic: Founded in 2013, BioLumic is a New Zealand and U.S.-based agricultural biotech company that programs plants and seeds with light to unlock growth, quality and health. The company's Light Signal Recipe™ platform combines biological data, plant science, and genetic marker knowledge to mediate genetic expression with a one-time application of light signals. BioLumic's Light Treatments are scalable and require no chemical application, genetic modification, facility expansion or large input costs. Contact us at www.biolumic.com or email to info@biolumic.com. About Fawn River Cultivation Company: Fawn River Cultivation Company is a vertically integrated seed to sale cannabis company headquartered in Constantine, Michigan. Our focus is to cultivate and provide only the highest quality cannabis flower and premium products while offering world class customer service to our customers. Fawn River Cultivation Company strives to build a trusted brand that honors the cannabis plant as a part of a comprehensive approach to health. Contact Details BioLumic Nicole Prenger nicole@agtechpr.com Fawn River Cultivation Company Jennifer Babcock jrbabcock@fawnrivercc.com Company Website https://www.biolumic.com

July 11, 2023 08:00 AM Central Daylight Time

Image

Scancell Holdings "well-financed" and continuing to pursue deals

Scancell Holdings PLC

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the clinical stage biopharmaceutical company's progress and financial position. Durrant starts by highlighting that Scancell has "plenty of money" before going into more detail about what's been happening with its two lead compounds, SCIB1 and Modi-1. She also touches on progress in the relationship with Genmab since signing a commercial licensing agreement last year, and clarifies that Scancell is continuing to pursue other such deals: "We've just signed an evaluation with a new company... and we're in current discussions with a second company about another potential deal." She adds that the company is "well financed" with a runway extending into the second half of 2024, but makes it clear that the continued emergence of promising clinical data could make a fundraise necessary - saying that "clearly a company of our size always needs to think about that as we go forward." Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 11, 2023 06:51 AM Eastern Daylight Time

Video

Healthcare

Nevis Brands CEO reveals success story and future growth plans

NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst

Symbiome Partners with THG Ingenuity to Scale E-Commerce Offerings

Revenue Increased 72% In Q1 2023 For Premier Packaging Corporation, A DSS, Inc. (NYSE: DSS) Wholly Owned Subsidiary

Cellular Goods provides update on King Tide Carbon integration

Mechelle Evans Announces GlowByMe, Her New Skincare Company

Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?

Fawn River Cultivation Company and BioLumic Unleash a New Era of Cannabis Varieties in Michigan

Scancell Holdings "well-financed" and continuing to pursue deals